Sophia and myriad partnered to introduce innovation in liquid biopsy

Image Credit: Cinical Lab Products

Announcement

Myriad Genetics, a known face of precision medicine and molecular diagnostic testing, and Sophia Genetics, a leading AI technology company revolutionizing precision medicine, have entered a smart partnership to offer and develop pharmaceutical companies' new innovative liquid biopsy companion diagnostic (CDx) test globally. This collaboration will accelerate myriad’s advanced laboratory potency in the US to contribute best to the global testing for clinical trials. Meanwhile, Sophia Genetics’ vast network of over 800 connected institutions in 70+ countries is there for test deployment globally.

President and CEO of Myriad Genetics, Sam Raha, said, “Delivering to healthcare providers and patients with the cancer care continuum is a smart and effective target for Myriad Genetics. We hope this partnership with Sophia Genetics will contribute to the development and commercialization of the robust CDx solutions for our biopharma partners, with the capability to excellently impact patients' lives. Also, integrate an essential product offering to the myriad menu and help with the growth of our CDx programs.”

Effective collaboration

Myriad and Sophia Genetics will mainly focus on the liquid biopsy application, MSK-ACCESS, fueled by SOPHIA DDM. It is established in partnership with Memorial Sloan Kettering Cancer Center. The MSK-ACCESS, fueled with SOPHIA DDM, is a creative liquid biopsy test that identifies actionable (curable) genomic alterations from an individual blood draw with the help of exclusive centric algorithms, which examine circulating tumor DNA (ctDNA). By preparing this application into a CDx excessive patients can have access to the benefits of the quality tumor profiling test, promoting personalized healthcare at its peak.

Myriad will apply for regulatory submission in the US, and Sophia Genetics will be responsible for managing regulatory submission outside the US. Together, both companies will partner throughout the developmental initiatives. This hybrid creative idea seems to enable pharmaceutical partners access to the main regulated markets worldwide.

Co-founder and CEO of Sophia Genetics, Jurgi Camblong, said, “This partnership marks a vital moment for the market. By merging the collective strength of a specialty lab leader and a decentralized testing network, we are focusing beyond the extensive access. We’ll be leading an innovative oncology testing while building a strong foundation for a new hybrid model in companion diagnostics. This partnership will help us to deliver pharmaceutical and clinical partners better, while leveraging the acceptability of liquid biopsy solutions across the main markets.”